Comparison of the Absorb bioresorbable vascular scaffold to the Xience durable polymer everolimus-eluting metallic stent in routine clinical practice: a propensity score-matched analysis from a multicenter registry

Bartłomiej Orlik; Krzysztof Milewski; Kamil Derbisz; Michał Jelonek; Patrycja Chrząszcz; Sonia Beil; Adam Młodziankowski; Wojciech Picheta; Piotr P. Buszman; Paweł E. Buszman

doi:10.5114/aic.2018.76406

eISSN: 1897-4295
ISSN: 1734-9338

Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2018
vol. 14

Send email

Copy url:

abstract:

Original paper

Comparison of the Absorb bioresorbable vascular scaffold to the Xience durable polymer everolimus-eluting metallic stent in routine clinical practice: a propensity score-matched analysis from a multicenter registry

Bartłomiej Orlik

,

Krzysztof Milewski

,

Kamil Derbisz

,

Michał Jelonek

,

Patrycja Chrząszcz

,

Sonia Beil

,

Adam Młodziankowski

,

Wojciech Picheta

,

Piotr P. Buszman

,

Paweł E. Buszman

Adv Interv Cardiol 2018; 14, 2 (52): 149–156

DOI: https://doi.org/10.5114/aic.2018.76406

Online publish date: 2018/06/19

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Orlik B, Milewski K, Derbisz K, et al. Comparison of the Absorb bioresorbable vascular scaffold to the Xience durable polymer everolimus-eluting metallic stent in routine clinical practice: a propensity score-matched analysis from a multicenter registry. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2018;14(2):149-156. doi:10.5114/aic.2018.76406.

APA

Orlik, B., Milewski, K., Derbisz, K., Jelonek, M., Chrząszcz, P.,  & Beil, S. et al. (2018). Comparison of the Absorb bioresorbable vascular scaffold to the Xience durable polymer everolimus-eluting metallic stent in routine clinical practice: a propensity score-matched analysis from a multicenter registry. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 14(2), 149-156. https://doi.org/10.5114/aic.2018.76406

Chicago

Orlik, Bartłomiej, Krzysztof Milewski, Kamil Derbisz, Michał Jelonek, Patrycja Chrząszcz, Sonia Beil,  and Adam Młodziankowski et al. 2018. "Comparison of the Absorb bioresorbable vascular scaffold to the Xience durable polymer everolimus-eluting metallic stent in routine clinical practice: a propensity score-matched analysis from a multicenter registry". Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej 14 (2): 149-156. doi:10.5114/aic.2018.76406.

Harvard

Orlik, B., Milewski, K., Derbisz, K., Jelonek, M., Chrząszcz, P., Beil, S., Młodziankowski, A., Picheta, W., Buszman, P.,  and Buszman, P. (2018). Comparison of the Absorb bioresorbable vascular scaffold to the Xience durable polymer everolimus-eluting metallic stent in routine clinical practice: a propensity score-matched analysis from a multicenter registry. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 14(2), pp.149-156. https://doi.org/10.5114/aic.2018.76406

MLA

Orlik, Bartłomiej et al. "Comparison of the Absorb bioresorbable vascular scaffold to the Xience durable polymer everolimus-eluting metallic stent in routine clinical practice: a propensity score-matched analysis from a multicenter registry." Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, vol. 14, no. 2, 2018, pp. 149-156. doi:10.5114/aic.2018.76406.

Vancouver

Orlik B, Milewski K, Derbisz K, Jelonek M, Chrząszcz P, Beil S et al. Comparison of the Absorb bioresorbable vascular scaffold to the Xience durable polymer everolimus-eluting metallic stent in routine clinical practice: a propensity score-matched analysis from a multicenter registry. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2018;14(2):149-156. doi:10.5114/aic.2018.76406.

Introduction
Most clinical trials related to bioresorbable vascular scaffold (BVS) technology are limited to a highly selected patient population.

Aim
To evaluate early and long-term clinical outcomes of the Absorb everolimus-eluting BVS compared to the everolimus-eluting metallic XIENCE V stent in routine clinical practice.

Material and methods
This is a multicenter, retrospective propensity score-matched comparative study, comprising 76 patients treated with a bare metal stents (BMS) and 501 with a XIENCE stent. Patients included in the study had stable and unstable angina and both types of myocardial infarction (STEMI and NSTEMI) as an indication for intervention and at least one significant de novo lesion in native coronary arteries. The primary endpoint was major adverse cardiovascular event (MACE), defined as death, myocardial infarction (MI), or target vessel revascularization (TVR).

Results
Median follow-up was 400 days in both groups. After propensity score matching for patient baseline characteristics, only higher rate of predilatation, predominantly treated left anterior descending artery (LAD) and lower number of used stents in the BVS group remained statistically significant. After adjustment there was no difference in type of treated lesions. The MACE rate did not differ between BVS and drug-eluting stents (DES) groups (7.2% vs. 11.15%, respectively; p = 0.17). The TVR was 2.9% in both groups. Except in the periprocedural period, there were no deaths or MI in the BVS group. There was no stent thrombosis in either studied group.

Conclusions
In routine clinical practice throughout long-term follow-up, clinical outcomes of patients who successfully received the Absorb BVS did not differ from those of patients who received the Xience stent. Longer follow-up data are required to determine whether these findings will persist beyond one year.

keywords:

Comparison of the Absorb bioresorbable vascular scaffold to the Xience durable polymer everolimus-eluting metallic stent in routine clinical practice: a propensity score-matched analysis from a multicenter registry

Bartłomiej Orlik , Krzysztof Milewski , Kamil Derbisz , Michał Jelonek , Patrycja Chrząszcz , Sonia Beil , Adam Młodziankowski , Wojciech Picheta , Piotr P. Buszman , Paweł E. Buszman

acute coronary syndrome, drug-eluting stent, stable angina, bioresorbable vascular scaffold, coronary percutaneous intervention

Bartłomiej Orlik

,

Krzysztof Milewski

,

Kamil Derbisz

,

Michał Jelonek

,

Patrycja Chrząszcz

,

Sonia Beil

,

Adam Młodziankowski

,

Wojciech Picheta

,

Piotr P. Buszman

,

Paweł E. Buszman